NCT06375512View on ClinicalTrials.gov

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

July 5, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

HZ Vaccine (IN001)

Formulation for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) for injection

BIOLOGICAL

Shingrix

Sterile suspension for injection

Trial Locations (3)

2019

Emeritus Research Pty Ltd, Sydney

3124

Emeritus Research Pty Ltd, Melbourne

33024

CenExel, Hollywood

All Listed Sponsors

lead

Shenzhen Shenxin Biotechnology Co., Ltd

INDUSTRY

NCT06375512 - A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants | Biotech Hunter | Biotech Hunter